PACT DAC

Chad C Smith
csmith@pactpharma.com

Request Access

Dataset ID	Description	Technology	Samples
EGAD00001009830	Sixteen patients with refractory solid cancers received up to three distinct neoTCR-transgenic cell products, each expressing a patient-specific neoTCR, in a cell dose-escalation, first-in-human phase 1 clinical trial (NCT03970382). Included are the tumor and normal WXS and tumor RNAseq for dosed patients.	Illumina HiSeq 2500	86